Revance Therapeutics (RVNC) Tops Q4 EPS by 13c

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.71), $0.13 better than the analyst estimate of ($0.84). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $130 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Creatd files Form S-1 and reports Q1 2026 financial results
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance